Endocrine Management of Prostatic Cancer / / H. Klosterhalfen.

Saved in:
Bibliographic Details
Superior document:Title is part of eBook package: De Gruyter DGBA Medicine and Life Sciences - <1990
HerausgeberIn:
:
Place / Publishing House:Berlin ;, Boston : : De Gruyter, , [2019]
©1988
Year of Publication:2019
Edition:Reprint 2019
Language:German
Series:New Developments in Biosciences ; 4
Online Access:
Physical Description:1 online resource (137 p.) :; Num. figs.
Tags: Add Tag
No Tags, Be the first to tag this record!
id 9783110853674
ctrlnum (DE-B1597)54261
(OCoLC)1105858979
collection bib_alma
record_format marc
spelling Endocrine Management of Prostatic Cancer / H. Klosterhalfen.
Reprint 2019
Berlin ; Boston : De Gruyter, [2019]
©1988
1 online resource (137 p.) : Num. figs.
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
text file PDF rda
New Developments in Biosciences ; 4
Frontmatter -- Contents -- I. Mechanism of hormonal action at cellular level and biochemistry -- Mechanism and effects of androgen withdrawal therapies / Bruchovsky, N. / Rennie, P. S. / Goldenberg, S. L. -- Target-cell response to androgen withdrawal / Voigt, K. D. / Klein, H. -- Effects of chronic treatment with an LH-RH agonist on human testis tissue / Huhtaniemi, I. T. -- Animal models for prostate cancer / Otto, U. / Wagner, B. / Kloppel, G. / Baisch, H. / Klosterhalfen, H. -- The significance of the nude mice model for studies on human prostatic carcinoma / Steenbrugge, G. J. van / Jong, F. H. de / Gallee, M. P. W. / Schroder, F. H. -- II. Etiology and experimental basis of therapy -- Etiology and natural history of early prostatic cancer / Schröder, F. H. -- Pharmacological basis of androgen deprivation by various antiandrogens and their combination with LH-RH agonists / Neumann, F. / El Etreby, M. F. / Habenicht, U.-F. / Radlmaier, A. / Bormacher, K. -- III. Clinics -- Evaluation of different endocrine approaches in the treatment of prostatic carcinoma / Turkes, A. O. / Peeling, W. B. / Wilson, D. W. / Griffiths, K. -- Rationale of total androgen blockade by cyproterone acetate / Tunn, U. W. -- Clinical experience with Androcur® in the treatment of prostatic cancer / Becker, H. / Klosterhalfen, H. -- Prostate cancer treatment: tolerance of different endocrine regimens / Varenhorst, E. -- Result of long-term treatment with cyproterone acetate (CPA) in advanced prostatic cancer patients / Di Silverio, F. / Sciarra, F. -- Results and experience with the androgen ablation therapy: current trends in the USA / Kirchheim, D. -- Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate / Jacobi, G. H. -- List of first-mentioned contributors
restricted access http://purl.org/coar/access_right/c_16ec online access with authorization star
Mode of access: Internet via World Wide Web.
In German.
Description based on online resource; title from PDF title page (publisher's Web site, viewed 21. Dez 2019)
Hormontherapie.
Modell.
Prostatakrebs.
MEDICAL / Clinical Medicine. bisacsh
Klosterhalfen, H., editor. edt http://id.loc.gov/vocabulary/relators/edt.
Title is part of eBook package: De Gruyter DGBA Medicine and Life Sciences - <1990 9783110637861 ZDB-23-GML
print 9783110115130
https://doi.org/10.1515/9783110853674
Cover https://www.degruyter.com/cover/covers/9783110853674.jpg
language German
format eBook
author2 Klosterhalfen, H.,
Klosterhalfen, H.,
author_facet Klosterhalfen, H.,
Klosterhalfen, H.,
author2_variant h k hk
h k hk
author2_role HerausgeberIn
author_sort Klosterhalfen, H.,
author_additional Bruchovsky, N. / Rennie, P. S. / Goldenberg, S. L. --
Voigt, K. D. / Klein, H. --
Huhtaniemi, I. T. --
Otto, U. / Wagner, B. / Kloppel, G. / Baisch, H. / Klosterhalfen, H. --
Steenbrugge, G. J. van / Jong, F. H. de / Gallee, M. P. W. / Schroder, F. H. --
Schröder, F. H. --
Neumann, F. / El Etreby, M. F. / Habenicht, U.-F. / Radlmaier, A. / Bormacher, K. --
Turkes, A. O. / Peeling, W. B. / Wilson, D. W. / Griffiths, K. --
Tunn, U. W. --
Becker, H. / Klosterhalfen, H. --
Varenhorst, E. --
Di Silverio, F. / Sciarra, F. --
Kirchheim, D. --
Jacobi, G. H. --
title Endocrine Management of Prostatic Cancer /
spellingShingle Endocrine Management of Prostatic Cancer /
New Developments in Biosciences ;
Frontmatter --
Contents --
I. Mechanism of hormonal action at cellular level and biochemistry --
Mechanism and effects of androgen withdrawal therapies /
Target-cell response to androgen withdrawal /
Effects of chronic treatment with an LH-RH agonist on human testis tissue /
Animal models for prostate cancer /
The significance of the nude mice model for studies on human prostatic carcinoma /
II. Etiology and experimental basis of therapy --
Etiology and natural history of early prostatic cancer /
Pharmacological basis of androgen deprivation by various antiandrogens and their combination with LH-RH agonists /
III. Clinics --
Evaluation of different endocrine approaches in the treatment of prostatic carcinoma /
Rationale of total androgen blockade by cyproterone acetate /
Clinical experience with Androcur® in the treatment of prostatic cancer /
Prostate cancer treatment: tolerance of different endocrine regimens /
Result of long-term treatment with cyproterone acetate (CPA) in advanced prostatic cancer patients /
Results and experience with the androgen ablation therapy: current trends in the USA /
Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate /
List of first-mentioned contributors
title_full Endocrine Management of Prostatic Cancer / H. Klosterhalfen.
title_fullStr Endocrine Management of Prostatic Cancer / H. Klosterhalfen.
title_full_unstemmed Endocrine Management of Prostatic Cancer / H. Klosterhalfen.
title_auth Endocrine Management of Prostatic Cancer /
title_alt Frontmatter --
Contents --
I. Mechanism of hormonal action at cellular level and biochemistry --
Mechanism and effects of androgen withdrawal therapies /
Target-cell response to androgen withdrawal /
Effects of chronic treatment with an LH-RH agonist on human testis tissue /
Animal models for prostate cancer /
The significance of the nude mice model for studies on human prostatic carcinoma /
II. Etiology and experimental basis of therapy --
Etiology and natural history of early prostatic cancer /
Pharmacological basis of androgen deprivation by various antiandrogens and their combination with LH-RH agonists /
III. Clinics --
Evaluation of different endocrine approaches in the treatment of prostatic carcinoma /
Rationale of total androgen blockade by cyproterone acetate /
Clinical experience with Androcur® in the treatment of prostatic cancer /
Prostate cancer treatment: tolerance of different endocrine regimens /
Result of long-term treatment with cyproterone acetate (CPA) in advanced prostatic cancer patients /
Results and experience with the androgen ablation therapy: current trends in the USA /
Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate /
List of first-mentioned contributors
title_new Endocrine Management of Prostatic Cancer /
title_sort endocrine management of prostatic cancer /
series New Developments in Biosciences ;
series2 New Developments in Biosciences ;
publisher De Gruyter,
publishDate 2019
physical 1 online resource (137 p.) : Num. figs.
edition Reprint 2019
contents Frontmatter --
Contents --
I. Mechanism of hormonal action at cellular level and biochemistry --
Mechanism and effects of androgen withdrawal therapies /
Target-cell response to androgen withdrawal /
Effects of chronic treatment with an LH-RH agonist on human testis tissue /
Animal models for prostate cancer /
The significance of the nude mice model for studies on human prostatic carcinoma /
II. Etiology and experimental basis of therapy --
Etiology and natural history of early prostatic cancer /
Pharmacological basis of androgen deprivation by various antiandrogens and their combination with LH-RH agonists /
III. Clinics --
Evaluation of different endocrine approaches in the treatment of prostatic carcinoma /
Rationale of total androgen blockade by cyproterone acetate /
Clinical experience with Androcur® in the treatment of prostatic cancer /
Prostate cancer treatment: tolerance of different endocrine regimens /
Result of long-term treatment with cyproterone acetate (CPA) in advanced prostatic cancer patients /
Results and experience with the androgen ablation therapy: current trends in the USA /
Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate /
List of first-mentioned contributors
isbn 9783110853674
9783110637861
9783110115130
url https://doi.org/10.1515/9783110853674
https://www.degruyter.com/cover/covers/9783110853674.jpg
illustrated Not Illustrated
doi_str_mv 10.1515/9783110853674
oclc_num 1105858979
work_keys_str_mv AT klosterhalfenh endocrinemanagementofprostaticcancer
status_str n
ids_txt_mv (DE-B1597)54261
(OCoLC)1105858979
carrierType_str_mv cr
hierarchy_parent_title Title is part of eBook package: De Gruyter DGBA Medicine and Life Sciences - <1990
is_hierarchy_title Endocrine Management of Prostatic Cancer /
container_title Title is part of eBook package: De Gruyter DGBA Medicine and Life Sciences - <1990
author2_original_writing_str_mv noLinkedField
noLinkedField
_version_ 1770177916610543616
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04134nam a22006375i 4500</leader><controlfield tag="001">9783110853674</controlfield><controlfield tag="003">DE-B1597</controlfield><controlfield tag="005">20191221113333.0</controlfield><controlfield tag="006">m|||||o||d||||||||</controlfield><controlfield tag="007">cr || ||||||||</controlfield><controlfield tag="008">191221s2019 gw fo d z ger d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783110853674</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/9783110853674</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-B1597)54261</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1105858979</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-B1597</subfield><subfield code="b">eng</subfield><subfield code="c">DE-B1597</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED014000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Endocrine Management of Prostatic Cancer /</subfield><subfield code="c">H. Klosterhalfen.</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">Reprint 2019</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin ;</subfield><subfield code="a">Boston : </subfield><subfield code="b">De Gruyter, </subfield><subfield code="c">[2019]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©1988</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (137 p.) :</subfield><subfield code="b">Num. figs.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="b">PDF</subfield><subfield code="2">rda</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">New Developments in Biosciences ;</subfield><subfield code="v">4</subfield></datafield><datafield tag="505" ind1="0" ind2="0"><subfield code="t">Frontmatter -- </subfield><subfield code="t">Contents -- </subfield><subfield code="t">I. Mechanism of hormonal action at cellular level and biochemistry -- </subfield><subfield code="t">Mechanism and effects of androgen withdrawal therapies / </subfield><subfield code="r">Bruchovsky, N. / Rennie, P. S. / Goldenberg, S. L. -- </subfield><subfield code="t">Target-cell response to androgen withdrawal / </subfield><subfield code="r">Voigt, K. D. / Klein, H. -- </subfield><subfield code="t">Effects of chronic treatment with an LH-RH agonist on human testis tissue / </subfield><subfield code="r">Huhtaniemi, I. T. -- </subfield><subfield code="t">Animal models for prostate cancer / </subfield><subfield code="r">Otto, U. / Wagner, B. / Kloppel, G. / Baisch, H. / Klosterhalfen, H. -- </subfield><subfield code="t">The significance of the nude mice model for studies on human prostatic carcinoma / </subfield><subfield code="r">Steenbrugge, G. J. van / Jong, F. H. de / Gallee, M. P. W. / Schroder, F. H. -- </subfield><subfield code="t">II. Etiology and experimental basis of therapy -- </subfield><subfield code="t">Etiology and natural history of early prostatic cancer / </subfield><subfield code="r">Schröder, F. H. -- </subfield><subfield code="t">Pharmacological basis of androgen deprivation by various antiandrogens and their combination with LH-RH agonists / </subfield><subfield code="r">Neumann, F. / El Etreby, M. F. / Habenicht, U.-F. / Radlmaier, A. / Bormacher, K. -- </subfield><subfield code="t">III. Clinics -- </subfield><subfield code="t">Evaluation of different endocrine approaches in the treatment of prostatic carcinoma / </subfield><subfield code="r">Turkes, A. O. / Peeling, W. B. / Wilson, D. W. / Griffiths, K. -- </subfield><subfield code="t">Rationale of total androgen blockade by cyproterone acetate / </subfield><subfield code="r">Tunn, U. W. -- </subfield><subfield code="t">Clinical experience with Androcur® in the treatment of prostatic cancer / </subfield><subfield code="r">Becker, H. / Klosterhalfen, H. -- </subfield><subfield code="t">Prostate cancer treatment: tolerance of different endocrine regimens / </subfield><subfield code="r">Varenhorst, E. -- </subfield><subfield code="t">Result of long-term treatment with cyproterone acetate (CPA) in advanced prostatic cancer patients / </subfield><subfield code="r">Di Silverio, F. / Sciarra, F. -- </subfield><subfield code="t">Results and experience with the androgen ablation therapy: current trends in the USA / </subfield><subfield code="r">Kirchheim, D. -- </subfield><subfield code="t">Long-term results of an LH-RH agonist monotherapy in patients with carcinoma of the prostate and reflections on the so-called total androgen blockade with pre-medicated cyproterone acetate / </subfield><subfield code="r">Jacobi, G. H. -- </subfield><subfield code="t">List of first-mentioned contributors</subfield></datafield><datafield tag="506" ind1="0" ind2=" "><subfield code="a">restricted access</subfield><subfield code="u">http://purl.org/coar/access_right/c_16ec</subfield><subfield code="f">online access with authorization</subfield><subfield code="2">star</subfield></datafield><datafield tag="538" ind1=" " ind2=" "><subfield code="a">Mode of access: Internet via World Wide Web.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In German.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (publisher's Web site, viewed 21. Dez 2019)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hormontherapie.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Modell.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prostatakrebs.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Clinical Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Klosterhalfen, H., </subfield><subfield code="e">editor.</subfield><subfield code="4">edt</subfield><subfield code="4">http://id.loc.gov/vocabulary/relators/edt.</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Title is part of eBook package:</subfield><subfield code="d">De Gruyter</subfield><subfield code="t">DGBA Medicine and Life Sciences - &lt;1990</subfield><subfield code="z">9783110637861</subfield><subfield code="o">ZDB-23-GML</subfield></datafield><datafield tag="776" ind1="0" ind2=" "><subfield code="c">print</subfield><subfield code="z">9783110115130</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/9783110853674</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="3">Cover</subfield><subfield code="u">https://www.degruyter.com/cover/covers/9783110853674.jpg</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">EBA_BACKALL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">EBA_CL_MDPM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">EBA_DGALL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">EBA_EBKALL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">EBA_STMALL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV-deGruyter-alles</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">PDA12STME</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">PDA14ALL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">PDA15STM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">PDA1ALL</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">PDA3STM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">PDA5EBK</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-23-GML</subfield><subfield code="b">1990</subfield></datafield></record></collection>